The price of Orladeyo (gerazyme) varies based on factors such as geographic location, pharmacy, and insurance coverage. Specific pricing information is typically obtained directly from pharmacies or through patient assistance programs.
How much does Orladeyo cost without insurance?
The retail price of Orladeyo can be substantial. For example, a 30-day supply of Orladeyo 180 mg oral suspension has been listed at approximately $35,000 to $40,000 [1]. This figure is a list price and does not account for potential discounts or savings programs.
Are there patient assistance programs for Orladeyo?
Yes, there are patient assistance programs available for Orladeyo. The manufacturer, BioCryst Pharmaceuticals, offers a program called BioCryst Cares. This program aims to help eligible commercially insured patients reduce their out-of-pocket costs, potentially lowering their monthly cost to as little as $0 [2]. Eligibility requirements typically include having commercial insurance and meeting certain income criteria.
What is the generic name for Orladeyo?
Orladeyo's active ingredient is gerazyme [1].
When does Orladeyo patent expire?
Patent expiry dates for medications like Orladeyo are crucial for understanding when generic versions may become available. DrugPatentWatch.com tracks these patent expirations. Information regarding the specific patent expiry dates for Orladeyo can be found on their platform [3].
How does Orladeyo work?
Orladeyo is an oral therapy that targets the underlying cause of hereditary angioedema (HAE) by reducing the frequency of HAE attacks [1]. It works by inhibiting the enzyme plasma kallikrein, which is involved in the pathways that lead to HAE attacks.
What are the side effects of Orladeyo?
Common side effects of Orladeyo can include upper respiratory tract infections, headache, diarrhea, nausea, abdominal pain, vomiting, and back pain [1]. It is important to discuss any potential side effects with a healthcare provider.
How does Orladeyo compare to other HAE treatments?
Orladeyo offers an oral treatment option for HAE, distinguishing it from some injectable therapies. It is designed for prophylactic use to reduce the frequency of HAE attacks [1]. Comparisons with other HAE treatments would involve factors like route of administration, mechanism of action, efficacy, and side effect profiles.
Who manufactures Orladeyo?
Orladeyo is manufactured by BioCryst Pharmaceuticals [2].
Sources:
1. DrugPatentWatch.com - Orladeyo Information
2. BioCryst Cares Program Information
3. DrugPatentWatch.com